FilingReader Intelligence
Alivus Life Sciences reports strong Q1 growth
August 1, 2025 at 07:06 PM UTC•By FilingReader AI
Alivus Life Sciences reported Q1 FY26 revenue of ₹6,018m, up 2.2% year-on-year, with EBITDA rising 9.9% to ₹1,813m and profit growing 9.0% to ₹1,215m.
The company's Non-GPL business grew 14.5% while GPL contributed around 25% of total revenue. Free cash flow reached ₹1,000m.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Please find attached herewith Allotment of Equity Shares under the ''Employee Stock Option Scheme, 2021''August 1, 2025 at 01:35 PM UTC
Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that the Board at its meeting held today approved the unaudited Financial Results for the First Quarter ended ....August 1, 2025 at 01:01 PM UTC
Please find attached herewith Investors Presentation.August 1, 2025 at 01:44 PM UTC
Please find attached herewith Press Release.August 1, 2025 at 01:41 PM UTC
BSE:GLS•Bombay Stock Exchange
News Alerts
Get instant email alerts when Glenmark Life Sciences publishes news
Free account required • Unsubscribe anytime